FRONTEO announces the successful creation of a pathway map for the novel coronavirus infection (COVID-19), using its proprietary AI system “Cascade Eye”.
The pathway map visually identifies crucial molecules, genes, and drug candidates in relation to COVID-19.
FRONTEO’s AI-powered drug discovery support tool “Cascade Eye” was able to analyze research about the genes and molecules to create a pathway map, making it possible to search for existing drug candidates to combat COVID-19.
“Cascade Eye” is powered by Concept Encoder (conceptencoder®), FRONTEO’s proprietary natural language processing AI engine, which analyzes molecular, genetic, and other information related to various diseases in a fraction of the time it takes humans, and is capable of visualizing this information in the form of a pathway map.
“Cascade Eye” was able to identify key molecules in COVID-19 that are targets of existing drugs to create a pathway map, unhindered by human prejudice or bias.
In addition to discovering new targets and biomarkers that may be overlooked because of human bias, it can also help predict the efficacy and safety of treatments using existing drugs. FRONTEO plans to publish the COVID-19 pathway map and make it widely available to both pharmaceutical companies and public institutions to aid in therapeutic drug selection and review
FRONTEO plans to publish the COVID-19 pathway map and make it widely available to both pharmaceutical companies and public institutions to aid in therapeutic drug selection and review.